These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28552242)

  • 1. [Switching from antipsychotics to aripiprazole and risk of agitation].
    Chaumette B; Masson M; Barde M; Gay O; Gaillard R
    Encephale; 2018 Feb; 44(1):88-90. PubMed ID: 28552242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia.
    Maat A; Cahn W; Gijsman HJ; Hovens JE; Kahn RS; Aleman A
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):575-84. PubMed ID: 24418213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aripiprazole, gambling disorder and compulsive sexuality].
    Mété D; Dafreville C; Paitel V; Wind P
    Encephale; 2016 Jun; 42(3):281-3. PubMed ID: 26923999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Paroxysmal Perceptual Alteration in Catatonic Schizophrenia by Switching to Aripiprazole from Risperidone: A Case Report.
    Yamashita S; Miyaoka T; Nagahama M; Ieda M; Tsuchie K; Wake R; Horiguchi J
    Clin Schizophr Relat Psychoses; 2016; 10(1):37-40. PubMed ID: 24047761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study.
    Liemburg EJ; van Es F; Knegtering H; Aleman A
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):112-119. PubMed ID: 28558941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
    Kittipeerachon M; Chaichan W
    Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
    Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
    J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
    Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
    Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
    Thone J
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):481-2. PubMed ID: 18070865
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
    Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular aripiprazole in the control of agitation.
    Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.